July 2026 Prescription Drug Affordability Board Meeting
Meeting Details
The Maryland Prescription Drug Affordability Board invites you to attend the July Board Meeting, scheduled for Monday, July 27, 2026 at 9:00 AM. The meeting will be held remotely. Part of the meeting may be conducted in closed session. Please register for the meeting here. After registering, you will receive a confirmation email with information about joining the webinar. PDAB staff politely requests that you mute your line after entering the meeting.
- Date and time: July 27th, 2026 2:00 pm to 4:00 pm
Public Comment
The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected] no later than the close of business on Wednesday, July 22, 2026, and provide:
- Your name
- Your address
- The agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.
Written Comment
The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please submit any written comments, concerning this agenda no later than the close of business on Wednesday, July 22, 2026. Please utilize the subject line “July 2026 Board Comments.”
Agenda and Meeting Materials
- Agenda (Revised July 20, 2026) - PDF - 119.5 KB
- Meeting Recording
- Proposed Revisions to COMAR 14.01.04 Cost Review Study Process- Clean - PDF - 352.43 KB(Posted July 20, 2026)
- Proposed Revisions to COMAR 14.01.04 Cost Review Study Process- Redlined - PDF - 284.84 KB (Posted July 20, 2026- Updated July 21, 2026)
- Consideration of Proposed Revisions to COMAR 14.01.01.05 General Provisions- Public Comment Procedures - PDF - 98.57 KB (Posted July 20, 2026- Updated July 22, 2026)
- Proposed Revisions to Cost Review Study Process COMAR 14.01.04- Presentation - PDF - 169.4 KB
- Written Comment Packet for draft proposed regulations COMAR 14.01.04 Cost Review Study Process - PDF - 2.92 MB(Due June 1, 2026)
- Written Comment Packet for draft proposed regulations COMAR 14.01.04.01 Cost Review Study Process-Circumstances Under Which Use of a Drug May Create an Affordability Challenge - PDF - 2.38 MB(Due June 26, 2026)
- Written Comment Packet for the July 27, 2026 Board Meeting - PDF - 2.01 MB
- Written Comments Received from the following:
- Boehringer Ingelheim
- Community Access National Network (CANN)
- Let My Doctors Decide Action Network
- Maryland Tech Council
- National Pharmaceutical Council
- Written Comments Received from the following: